MDCX News & Events

Medicus Pharma announces topline results from its Phase 2 clinical study evaluating safety and efficacy of Doxorubicin Microneedle Array, D-MNA, to non-invasively treat basal cell carcinoma of the skin. The Company believes the topline results are not only positive but decision-grade that should support an end of phase 2 meeting with the FDA in the first half of 2026 as well as accelerate partnering readiness. "We are extremely encouraged by these topline results, which not only validate management's scientific and investment thesis, but also provide what we consider to be decision-grade evidence of clinical activity, particularly at the 200-microgram dose level," said Dr. Raza Bokhari, Executive Chairman & CEO of Medicus.

Medicus Pharma announces topline results from its Phase 2 clinical study evaluating safety and efficacy of Doxorubicin Microneedle Array, D-MNA, to non-invasively treat basal cell carcinoma of the skin. The Company believes the topline results are not only positive but decision-grade that should support an end of phase 2 meeting with the FDA in the first half of 2026 as well as accelerate partnering readiness. "We are extremely encouraged by these topline results, which not only validate management's scientific and investment thesis, but also provide what we consider to be decision-grade evidence of clinical activity, particularly at the 200-microgram dose level," said Dr. Raza Bokhari, Executive Chairman & CEO of Medicus.

New to The Street has signed a six-part media series with Medicus Pharma. The comprehensive series is designed to elevate Medicus' visibility with institutional investors, analysts, and the broader healthcare and life sciences community through a multi-channel media and investor engagement strategy. The engagement will spotlight Medicus Pharma's clinical progress, management vision, and long-term growth opportunities, delivering consistent, high-quality exposure over the course of the engagement.

Medicus Pharma announces that it has received "study may proceed" clearance from the U.S. Food and Drug Administration, FDA, to initiate its Phase 2b dose-optimization study of Teverelix, an investigational next generation long-acting GnRH antagonist, in men with advanced prostate cancer, APC.